> Details

Dodaran, Masoud Solaymani; Banihashemi, Seyed Reza; Es-haghi, Ali; Mehrabadi, Mohammad Hossein Fallah; Nofeli, Mojtaba; Mokarram, Ali Rezaei; Mokhberalsafa, Ladan; Sadeghi, Fariba; Ranjbar, Alireza; Ansarifar, Akram; Mohazzab, Arash; Setarehdan, Seyed Amin; Bagheri Amiri, Fahimeh; Mohseni, Vahideh; Hajimoradi, Monireh; Ghahremanzadeh, Neda; Razzaz, Seyed Hossein; Masoomi, Safdar; Taghdiri, Maryam; Bagheri, Mohsen; Lofti, Mohsen; Khorasani, Akbar; Ghader, Masoud; Safari, Shiva; [...]

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial
  • Contributor: Dodaran, Masoud Solaymani; Banihashemi, Seyed Reza; Es-haghi, Ali; Mehrabadi, Mohammad Hossein Fallah; Nofeli, Mojtaba; Mokarram, Ali Rezaei; Mokhberalsafa, Ladan; Sadeghi, Fariba; Ranjbar, Alireza; Ansarifar, Akram; Mohazzab, Arash; Setarehdan, Seyed Amin; Bagheri Amiri, Fahimeh; Mohseni, Vahideh; Hajimoradi, Monireh; Ghahremanzadeh, Neda; Razzaz, Seyed Hossein; Masoomi, Safdar; Taghdiri, Maryam; Bagheri, Mohsen; Lofti, Mohsen; Khorasani, Akbar; Ghader, Masoud; Safari, Shiva; [...]
  • imprint: MDPI AG, 2023
  • Published in: Vaccines
  • Language: English
  • DOI: 10.3390/vaccines11020455
  • ISSN: 2076-393X
  • Keywords: Pharmacology (medical) ; Infectious Diseases ; Drug Discovery ; Pharmacology ; Immunology
  • Origination:
  • Footnote:
  • Description: <jats:p>Objectives: This study aimed to determine the safety and immunogenicity of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). Methods: We conducted a randomized, double-blind, placebo-controlled, phase I trial. Three vaccine strengths were compared with an adjuvant-only preparation. It included two intramuscular and a third intranasal dose. Eligible participants were followed for adverse reactions. Specific IgG, secretory IgA, neutralizing antibodies, and cell-mediated immunity were assessed. Results: A total of 153 participants were enrolled (13 sentinels, 120 randomized, 20 non-randomized open-labeled for IgA assessment). No related serious adverse event was observed. The geometric mean ratios (GMRs) and 95% CI for serum neutralizing antibodies compared with placebo two weeks after the second injection were 5.82 (1.46–23.13), 11.12 (2.74–45.09), and 20.70 (5.05–84.76) in 5, 10, and 20 µg vaccine groups, respectively. The GMR for anti-RBD IgA in mucosal fluid two weeks after the intranasal dose was 23.27 (21.27–25.45) in the 10 µg vaccine group. The humoral responses were sustained for up to five months. All vaccine strengths indicated a strong T-helper 1 response. Conclusion: RCP is safe and creates strong and durable humoral and cellular immunity and good mucosal immune response in its 10 µg /200 µL vaccine strengths. Trial registration: IRCT20201214049709N1.</jats:p>
  • Access State: Open Access